Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk

This study has been completed.
Sponsor:
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00839696
First received: February 5, 2009
Last updated: December 5, 2014
Last verified: December 2014

February 5, 2009
December 5, 2014
July 2008
June 2009   (final data collection date for primary outcome measure)
Characterize the distribution of total xenoestrogen burden and identify important source of xenoestrogen exposure among a clinic-based sample of postmenopausal women. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00839696 on ClinicalTrials.gov Archive Site
Evaluate the association of total xenoestorgen exposure with mammographic density. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Mammographic density is sensitive to estorgen exposure and constitutes a strong intermediate maker of breast cancer risk. We hypothesize that women with higher serum xenoestrogen levels will have greater mammographic density.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Serum Xenoestrogen
Probability Sample
Subjects recruited from screening mammography population
Breast Cancer Risk
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
270
April 2010
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 55-70 years of age, Post menopausal

Exclusion Criteria:

  • If they have ever used hormone replacment therapy or have ever used Tamoxifen or Raloxifene, Diag. with breast cancer have had breast implants or have had a mastectomy/
Female
55 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00839696
CC07104
No
Not Provided
Not Provided
University of Wisconsin, Madison
University of Wisconsin, Madison
United States Department of Defense
Principal Investigator: Amy Trentham Dietz, PhD Associate Professor- Population Health Sciences, UW School of Medicine and Public Health
University of Wisconsin, Madison
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP